Disclosed is a fused ring compound and an application thereof. Disclosed is a fused ring compound represented by formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, an isotope compound, a crystal form, a nitrogen oxide, a solvate, or a solvate of the pharmaceutically acceptable salt thereof. The fused ring compound of the present invention has high P2X4 antagonistic activity, excellent selectivity, low toxicity and excellent metabolic stability.

##STR00001##

Disclosed is a fused ring compound and an application thereof. Disclosed is a fused ring compound represented by formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, an isotope compound, a crystal form, a nitrogen oxide, a solvate, or a solvate of the pharmaceutically acceptable salt thereof. The fused ring compound of the present invention has high P2X4 antagonistic activity, excellent selectivity, low toxicity and excellent metabolic stability.

##STR00001##

The present invention provides a heterocyclic compound having an RORγt inhibitory action. The present invention relates to a compound represented by the formula (I): ##STR00001##
wherein
Ar is a the partial structure (1) to the partial structure (5),
Q is a bivalent group selected from the group consisting of (Ia)-(If), and
B is a ring optionally having substituent(s),
or a salt thereof.

The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.

The application relates to novel sulfoximine substituted quinazoline derivatives of formula (I) wherein Ar, R.sup.1, R.sup.2 and R.sup.3 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

##STR00001##

The present invention provides a cured product obtained by curing a curable composition including a compound represented by General Formula 1, in which a birefringence Δn (587 nm) is 0.00≤Δn (587 nm)≤0.01.
Pol.sub.1-Sp.sub.1-L.sub.1-Ar-L.sub.2-Sp.sub.2-Pol.sub.2  (General Formula 1) In the formula, Ar represents a divalent group containing a ring structure selected from the group consisting of a quinoxaline ring and a quinazoline ring; L.sub.1 and L.sub.2 each represent a single bond, —O—, —OC(═O)—, —OC(═O)O—, —OC(═O)NH—, and the like; Sp.sub.1 and Sp.sub.2 each represent a single bond or a divalent linking group; Pol.sub.1 and Pol.sub.2 each represent a hydrogen atom or a polymerizable group; and the compound represented by General Formula 1 has at least one polymerizable group. The cured product of the present invention has a small Abbe number (νd) and a large partial dispersion ratio (θg, F), and is therefore useful for production of optical members.

The present invention provides a cured product obtained by curing a curable composition including a compound represented by General Formula 1, in which a birefringence Δn (587 nm) is 0.00≤Δn (587 nm)≤0.01.
Pol.sub.1-Sp.sub.1-L.sub.1-Ar-L.sub.2-Sp.sub.2-Pol.sub.2  (General Formula 1) In the formula, Ar represents a divalent group containing a ring structure selected from the group consisting of a quinoxaline ring and a quinazoline ring; L.sub.1 and L.sub.2 each represent a single bond, —O—, —OC(═O)—, —OC(═O)O—, —OC(═O)NH—, and the like; Sp.sub.1 and Sp.sub.2 each represent a single bond or a divalent linking group; Pol.sub.1 and Pol.sub.2 each represent a hydrogen atom or a polymerizable group; and the compound represented by General Formula 1 has at least one polymerizable group. The cured product of the present invention has a small Abbe number (νd) and a large partial dispersion ratio (θg, F), and is therefore useful for production of optical members.

The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.

The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.

The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.